Latest News

Ninlaro maintenance therapy extends PFS in posttransplant myeloma

Maintenance therapy with ixazomib significantly extended PFS compared with placebo for certain patients with myeloma, according to the agent’s manufacturer.
Ixazomib (Ninlaro, Takeda), an oral proteasome inhibitor, is approved for use in combination with lenalidomide (Revlimid, Celgene) and dexamethasone for patients with multiple myeloma who received at least one prior treatment. The agent — which is not approved as maintenance therapy for myeloma after autologous stem cell transplant — remains under investigation for a variety of myeloma treatment settings, as well as for

Related posts

Don't wait to follow up on eye doctor recommendations


Japanese Water Therapy For Better Health: Does It Work


Purdue Pharma touts data to fight lawsuits that downplay its role in the opioid epidemic


Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy